A pregnant woman at 36 weeks of gestation with a prosthetic valve replacement for mitral stenosis is on warfarin therapy. Her INR is 3. What is the appropriate next step in management ? LMWH- Low Molecular Weight Heparin

Explanation

## Correct Answer: B. Stop warfarin and start LMWH At 36 weeks of gestation, warfarin is contraindicated due to its teratogenic effects, particularly the risk of fetal warfarin syndrome (characterized by nasal hypoplasia, skeletal abnormalities, and CNS defects) and increased risk of fetal hemorrhage, especially in the third trimester. The standard Indian obstetric guideline (as per FOGSI and RCOG recommendations adopted in India) mandates switching from warfarin to LMWH by 36 weeks in pregnant women with prosthetic valves. LMWH (enoxaparin or dalteparin) does not cross the placenta, making it safe for the fetus. An INR of 3 indicates therapeutic anticoagulation on warfarin, but this does not change the management—the timing of pregnancy (third trimester) is the overriding factor. LMWH provides adequate anticoagulation for prosthetic valve protection while minimizing fetal risk. The switch should occur at 36 weeks to allow time for labor and delivery while maintaining anticoagulation. LMWH is continued until labor onset, at which point unfractionated heparin (UFH) is preferred for its shorter half-life and reversibility with protamine. ## Why the other options are wrong **A. Continue warfarin** — This is wrong because warfarin is absolutely contraindicated in the third trimester of pregnancy due to teratogenicity and increased fetal hemorrhage risk. Continuing warfarin at 36 weeks violates standard obstetric practice in India and internationally. The INR being therapeutic does not justify continuation—the gestational age is the critical decision point. **C. Stop warfarin, start LMWH and aspirin** — This is wrong because adding aspirin to LMWH in a pregnant woman with a prosthetic valve is not standard practice and increases bleeding risk without additional benefit. LMWH alone provides sufficient anticoagulation for prosthetic valve protection. Aspirin is reserved for specific indications (e.g., prior thrombotic events) and is not routinely combined with LMWH in this setting. **D. Stop warfarin and start heparin** — This is wrong because unfractionated heparin (UFH) is not preferred for long-term anticoagulation in pregnancy before labor. LMWH is superior due to better bioavailability, longer half-life, more predictable pharmacokinetics, and once or twice-daily dosing. UFH is reserved for the intrapartum period when its reversibility with protamine is advantageous. ## High-Yield Facts - **Warfarin is contraindicated in the third trimester** of pregnancy due to fetal warfarin syndrome (nasal hypoplasia, skeletal abnormalities, CNS defects) and fetal hemorrhage risk. - **LMWH is the anticoagulant of choice** from 36 weeks onward in pregnant women with prosthetic valves because it does not cross the placenta and provides reliable anticoagulation. - **Switch from warfarin to LMWH at 36 weeks** is the standard Indian obstetric guideline (FOGSI/RCOG-adopted) for all pregnant women on warfarin with mechanical prosthetic valves. - **LMWH dosing in pregnancy** requires dose adjustment based on weight and anti-Xa levels (target 0.5–1.2 IU/mL for therapeutic anticoagulation); standard dosing may be insufficient. - **Unfractionated heparin (UFH) is preferred intrapartum** due to its short half-life and reversibility with protamine; LMWH is switched to UFH when labor begins or at term. ## Mnemonics **WAR-BABY rule** **W**arfarin in **A**ll **R**trimesters is bad for **B**aby; switch to **A**nticoagulant (LMWH) by **B**eginning of third trimester, then **Y** (UFH) at labor. **3-6-9 rule for prosthetic valve anticoagulation in pregnancy** First trimester (0–12 weeks): UFH or LMWH; Second trimester (13–28 weeks): Warfarin safe; Third trimester (29+ weeks, especially 36+ weeks): LMWH only. Switch at 36 weeks, not before. ## NBE Trap NBE may trap students who focus on the INR value (3 = therapeutic) and assume warfarin should be continued. The key discriminator is gestational age (36 weeks = third trimester), not INR level. Students unfamiliar with Indian obstetric guidelines may also confuse LMWH with UFH or incorrectly add aspirin. ## Clinical Pearl In Indian obstetric practice, the "36-week switch" is a critical safety milestone: any pregnant woman with a prosthetic valve on warfarin must be switched to LMWH by 36 weeks, regardless of INR. This protects the fetus from warfarin teratogenicity while maintaining maternal valve protection. Many maternal deaths in India occur when this guideline is overlooked, making it a high-yield, high-stakes concept for NEET PG. _Reference: DC Dutta's Textbook of Obstetrics (Ch. 24: Cardiac Disease in Pregnancy); FOGSI Guidelines on Anticoagulation in Pregnancy; Harrison's Principles of Internal Medicine Ch. 282 (Pregnancy and Cardiovascular Disease)_